GILD

Business profile & competitive position

Gilead Sciences, Inc. (GILD) sits in the Healthcare sector under the Drug Manufacturers – General industry. That classification means it is a large-cap biopharmaceutical company generating revenue primarily from patented, reimbursed medicines. The current financial footprint, however, does not show the kind of margin power normally associated with a wide competitive moat: trailing-12-month net margin is –10.6% and return on equity is –16.3%. Both figures are negative, so over the reported window Gilead’s bottom line has shrunk rather than expanded. A negative ROE of this size indicates the company is currently destroying, not compounding, book value per dollar of shareholder equity. The $187.4 billion market capitalization still prices the stock as a major pharma franchise, but the margin data suggests near-term pricing or cost pressure rather than durable excess profitability.

Financial posture

Gilead’s most visible valuation metric is distorted by losses: the trailing P/E is –58.1, driven by the negative net margin of –10.6%. With the stock at $150.96, the market is clearly looking past the trailing loss and toward future cash flows, but a negative P/E means standard earnings-multiple comparisons with profitable drug peers are not meaningful today. Profitability signals are similarly weak: ROE is –16.3%, and the latest quarterly result on 2026-08-04 produced a net loss of –$6.75 per share versus the market’s real expectation of –$7.25. On the risk side, beta is only 0.35, so the equity has historically moved less than one-third as much as the broad market, consistent with a defensive Healthcare name even while its earnings profile is under pressure. Technically, the stock is above its 50-day EMA of $141.88 with an RSI of 63.3, sitting just below the commonly watched 70 overbought threshold.

Macro & geopolitical exposure

As a Drug Manufacturers – General company, Gilead is exposed to the standard macro and geopolitical forces that shape the pharmaceutical industry. Regulation is the most direct channel: FDA approvals, label expansions, manufacturing inspections, and safety reviews can all move revenue and stock price quickly. Reimbursement policy matters equally; Medicare, Medicaid, and private-payer pricing pressure can compress margins for both new launches and mature franchises. Trade and intellectual-property policy affect patent enforcement and the ability to maintain exclusivity in major markets, while foreign-exchange swings influence the dollar value of overseas sales. Supply-chain exposure to active pharmaceutical ingredients and biologics manufacturing, plus changes in global public-health funding, are also relevant for any general drug manufacturer. Litigation risk—common across the industry for product-liability and antitrust matters—can produce one-time charges large enough to flip a quarter from profit to loss.

Recent developments

The most prominent recent catalyst is the push around Gilead’s investigational once-yearly drug lenacapavir for HIV prevention. On 2026-09-16, Business Wire reported that Gilead is “accelerating global access planning” for the therapy, and Zacks followed the same day with coverage of a new PAHO deal in Latin America. The next day, 2026-09-17, Zacks noted heavy investor interest in Gilead, while AHF described the PAHO-Gilead HIV prevention agreement as a victory for civil society, also via Business Wire. Taken together, the headlines frame a company trying to build demand and access scaffolding for a long-acting HIV prevention product before what could be a major commercial launch. The PAHO region is a meaningful public-health channel for HIV medicines, so access negotiations there are relevant both for public-health stakeholders and for the revenue trajectory of any future launch.

Earnings behavior & post-earnings drift

Gilead’s earnings track record over the past two years is mechanically strong but has not always translated into immediate upward price action. The company has beaten estimates in all 8 of the last 8 reported quarters, a 100% beat rate, with an average earnings surprise of 9.7%. Over the same period, the average 5-day post-earnings drift has been positive at +1.71%, classified as “up.”

Looking at the most recent four quarters, the pattern is more nuanced. On 2026-08-04, Gilead reported –$6.75 EPS versus the –$7.25 unofficial consensus, a 6.9% positive surprise, yet the stock fell 2.58% the next day and only gained 0.38% over the following five days. The prior quarter, 2026-05-07, delivered $2.03 EPS against a $1.91 estimate, a 6.3% beat, but the next-day reaction was again negative at –2.04%, with a five-day drift of –1.49%. A clearer reward came on 2026-02-10, when a 2.8% beat ($1.86 vs. $1.81) produced a 5.82% next-day jump and a 3.74% five-day gain. The largest surprise in the sample, on 2025-10-30, saw EPS of $2.47 versus the market’s real expectation of $2.13, a 16% positive surprise; the stock rose 1.14% the next day and drifted 4.19% higher over five sessions.

The discrepancy between consistently positive earnings surprises and sometimes negative immediate reactions is a reminder that post-earnings moves depend on management guidance, full-year revisions, and segment commentary as much as on the headline EPS number. The next scheduled report is 2026-10-29 after the close, with the current consensus EPS estimate at $2.15.

If you want to take the analysis further, review the full institutional verdict on Gilead, including sell-side rating distributions, revision trends, and forward valuation models, alongside the figures above before forming your own view.